Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

In Fig 2, the delta and p-value are missing for the last available post-baseline assessment. The missing information reflects a statistically significant difference in the mean TWSTRS total score of aboBoNT-A vs placebo at the last available data point. Please see the correct Fig 2 here.

Fig 2. Mean TWSTRS total score.

aboBoNT-A = abobotulinumtoxinA; ITT = intent-to-treat (all randomized patients); last available* = last available post-baseline (end of study or early withdrawal); TWSTRS = Toronto Western Spasmodic Torticollis Rating Scale; Δ = weighted overall treatment difference. Error lines indicate standard deviation. *Last available = last available post-baseline (end of study or early withdrawal), mean (SD) study drug exposure: 62.6 (37.8) days.